GSA Capital Partners LLP Takes $1.33 Million Position in Zoetis Inc. $ZTS

GSA Capital Partners LLP bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 18,470 shares of the company’s stock, valued at approximately $1,327,000.

Other hedge funds have also added to or reduced their stakes in the company. J. Stern & Co. LLP boosted its stake in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. Norges Bank bought a new position in Zoetis during the 4th quarter worth $734,425,000. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis during the first quarter worth $286,660,000. Finally, Van ECK Associates Corp boosted its position in shares of Zoetis by 269.0% in the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after acquiring an additional 1,740,113 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 1.5%

Shares of NYSE ZTS opened at $72.71 on Tuesday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $160.48. The stock has a market capitalization of $30.05 billion, a P/E ratio of 11.98, a PEG ratio of 1.28 and a beta of 0.73. The stock’s fifty day moving average is $76.17 and its 200 day moving average is $98.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the firm earned $1.76 earnings per share. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. Zoetis’s payout ratio is presently 34.93%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Citigroup lowered their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.